Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.39 |
| ▸ | TACR3 | P29371 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19102772 | 0.94 | MEN1 (0.42) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL17435505 | 0.91 | DHODH (0.39) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL17435534 | 0.90 | MEN1 (0.39) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL17435731 | 0.87 | MEN1 (0.40) | MEN1KMT2ACYP3A4DHODHTACR3 | |
| SCHEMBL19102589 | 0.85 | DHODH (0.40) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL15529715 | 0.85 | MEN1 (0.41) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL19102763 | 0.84 | MEN1 (0.45) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL19102701 | 0.84 | MEN1 (0.41) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL17435762 | 0.84 | KMT2A (0.41) | MEN1KMT2ACYP3A4CYP2C9DHODH | |
| SCHEMBL17435550 | 0.84 | MEN1 (0.38) | MEN1KMT2ACYP3A4CYP2C9DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-12-28 | — | — | US | claimed |
| US-20160280639-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-09-29 | — | — | US | claimed |
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-01-21 | — | — | US | claimed |
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9701622-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701622-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701622-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160280639-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280639-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280639-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9403758-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403758-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403758-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | MEN1 2371/4885KMT2A 4840/4885CYP3A4 606/4885 |
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | MEN1 2371/4885KMT2A 4840/4885CYP3A4 606/4885 |
| US-20160280639-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | MEN1 2371/4885KMT2A 4840/4885CYP3A4 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.